Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(4), 1340-1344 | ISSN:2251-6727

Modern Bioanalytical Strategies for Olanzapine Detection and Analysis: An In-Depth Review

[1]Asit Baran Panigrahy*, Sudhir Kumar Sahoo[1], Ghanshyam Panigrahy[1]

[1]*Royal College of Pharmacy and Health Sciences, Berhampur, Odisha-760002, India.*

*Corresponding authors Email: asitpanigrahy@gmail.com

(**Received**: 14 April 2024 **Revised**: 01 May 2024 **Accepted**: 18 June 2024)

KEYWORDS

Olanzapine, Bioanalytical strategies, HPLC-MS/MS, Spectroscopy, Electrochemical sensors, Nanotechnology.

ABSTRACT:

Olanzapine, a second-generation antipsychotic, is essential for treating psychiatric conditions such as schizophrenia and bipolar disorder. Given its narrow therapeutic window and potential for significant side effects, precise monitoring of olanzapine plasma levels is crucial to ensure therapeutic efficacy and patient safety. This review provides an in-depth examination of modern bioanalytical strategies employed for the detection and quantification of olanzapine. It explores various advanced chromatographic techniques, such as high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography (UHPLC), coupled with tandem mass spectrometry (MS/MS) for enhanced sensitivity and specificity. Additionally, the review covers spectroscopic methods, including UV-visible and fluorescence spectroscopy, which offer rapid and cost-effective alternatives, although often requiring derivatization for improved selectivity. Emerging sensor-based approaches, such as electrochemical and optical sensors, are highlighted for their potential in real-time, on-site detection of olanzapine with high sensitivity. These methods benefit from the incorporation of nanomaterials and molecularly imprinted polymers (MIPs), which significantly enhance their performance. The review discusses the advantages and limitations of each analytical strategy, providing a comprehensive overview of the current state of olanzapine bioanalysis. It also highlights future prospects, emphasizing the development of hybrid techniques and novel sensor platforms driven by advancements in nanotechnology and materials science. By presenting these advancements, this review aims to guide future research efforts towards improving the analytical performance and clinical applicability of olanzapine detection methods, ultimately contributing to better therapeutic drug monitoring, pharmacokinetic studies, and patient outcomes.

1. Introduction

Olanzapine, a second-generation antipsychotic, is widely prescribed for the treatment of schizophrenia and bipolar disorder. Its therapeutic efficacy is attributed to its antagonistic effects on dopamine and serotonin receptors, making it a cornerstone in modern psychiatric treatment [1]. However, olanzapine's narrow therapeutic window necessitates precise monitoring to avoid adverse effects such as metabolic syndrome, weight gain, and diabetes [2]. Consequently, accurate and reliable bioanalytical methods are crucial for optimizing therapeutic outcomes and ensuring patient safety. High-performance liquid chromatography (HPLC) coupled with various detection systems has been the gold standard for olanzapine bioanalysis due to its robustness and high sensitivity [3]. HPLC-UV and HPLC-fluorescence are widely used for their simplicity and cost-effectiveness [4,5]. However, the integration of tandem mass spectrometry (MS/MS) with HPLC has significantly enhanced sensitivity and specificity, establishing HPLC-MS/MS as the preferred method for clinical and pharmacokinetic studies [6,7]. The development of ultra-high-performance liquid chromatography (UHPLC) has further improved resolution and analysis speed, making it an invaluable tool in olanzapine bioanalysis [8].

Spectroscopic methods, including UV-visible and fluorescence spectroscopy, also play significant roles in olanzapine detection. These techniques offer rapid and cost-effective alternatives to chromatographic methods but often require complex sample preparation or derivatization to achieve necessary selectivity and sensitivity [9]. Advances in fluorescence spectroscopy, such as derivative fluorescence methods, have improved detection limits and broadened the applicability of these techniques for olanzapine analysis [10].

Emerging sensor-based approaches, such as electrochemical and optical sensors, provide promising alternatives for on-site and real-time detection of

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(4), 1340-1344 | ISSN:2251-6727

olanzapine. Electrochemical sensors, including voltammetric and amperometric sensors, offer high sensitivity and rapid response times [11,12]. Optical sensors, utilizing technologies like surface plasmon resonance (SPR) and fluorescence resonance energy transfer (FRET), enable non-invasive and highly sensitive detection [13,14]. These sensor technologies, often enhanced by nanomaterials and molecularly imprinted polymers (MIPs), represent significant advancements in bioanalytical chemistry [15].

Despite these advancements, challenges remain in balancing sensitivity, specificity, speed, and ease of use. Future research is expected to focus on hybrid techniques that combine the strengths of different methods and on the development of novel sensor platforms driven by advancements in nanotechnology and materials science. This review aims to provide a comprehensive overview of the current state of olanzapine bioanalysis, discussing the advantages, limitations, and future prospects of various analytical strategies. By highlighting these advancements, we hope to guide future research efforts toward enhancing the analytical performance and clinical applicability of olanzapine detection methods.

2. Chromatographic Techniques

High-Performance Liquid Chromatography (HPLC)

HPLC remains the gold standard in olanzapine bioanalysis due to its robustness, sensitivity, and versatility. Various HPLC methods have been developed, utilizing different detection systems such as UV, fluorescence, and mass spectrometry (MS).

HPLC-UV: Commonly employed for its simplicity and cost-effectiveness, HPLC-UV methods have been optimized for olanzapine detection in plasma and urine samples. Methods often involve solid-phase extraction (SPE) for sample preparation, ensuring minimal interference and high recovery rates [16].

HPLC-Fluorescence: Enhanced sensitivity is achieved using fluorescence detection, allowing for lower limits of detection (LOD) and quantification (LOQ). This method is particularly useful for monitoring olanzapine in low-concentration samples, such as cerebrospinal fluid [17].

HPLC-MS/MS: The integration of tandem mass spectrometry with HPLC provides unparalleled sensitivity and specificity. HPLC-MS/MS is extensively used for pharmacokinetic studies, enabling the simultaneous quantification of olanzapine and its metabolites with high precision [18].

3. Ultra-High-Performance Liquid Chromatography (UHPLC)

UHPLC offers significant improvements in resolution, speed, and sensitivity compared to conventional HPLC. This technique employs columns with smaller particle sizes, leading to better separation efficiency and faster analysis times.

UHPLC-MS/MS: Combining UHPLC with MS/MS enhances detection capabilities, allowing for ultra-trace analysis of olanzapine in complex biological matrices. Recent advancements have focused on optimizing mobile phase compositions and gradient elution programs to further improve analytical performance [19].

4. Spectroscopic Methods

UV-Visible Spectroscopy

UV-Visible spectroscopy is widely used due to its simplicity and rapid analysis time. However, its application in olanzapine detection is limited by the need for derivatization or complex sample preparation to enhance selectivity.

Fluorescence Spectroscopy

Fluorescence spectroscopy offers higher sensitivity and selectivity compared to UV-Visible methods. The inherent fluorescence of olanzapine can be exploited, or fluorescence derivatizing agents can be used to improve detection limits.

1. **Direct Fluorescence**: Utilizes the native fluorescence properties of olanzapine, providing a straightforward and cost-effective method for its quantification in plasma and other biological fluids [20].
2. **Derivative Fluorescence**: Involves the use of fluorescent reagents to form highly fluorescent derivatives of olanzapine, enhancing sensitivity and selectivity. This approach is beneficial for detecting low concentrations of olanzapine in complex matrices [21].

5. Sensor-Based Approaches

Electrochemical Sensors

Electrochemical sensors have gained popularity due to their high sensitivity, rapid response, and potential for miniaturization. Various types of sensors, including voltammetric and amperometric sensors, have been developed for olanzapine detection.

Voltammetric Sensors: These sensors rely on the electrochemical oxidation or reduction of olanzapine at the electrode surface. Modifications of the electrode surface with nanomaterials or molecularly imprinted polymers (MIPs) have significantly improved the sensitivity and selectivity of these sensors [22].

Amperometric Sensors: Based on the measurement of current resulting from the electrochemical reaction of olanzapine, these sensors provide rapid and accurate quantification. Recent advancements include the development of enzyme-based sensors, which offer enhanced selectivity [23].

6. Optical Sensors

Optical sensors, including those based on surface plasmon resonance (SPR) and fluorescence resonance energy transfer (FRET), offer non-invasive and highly sensitive detection of olanzapine.

SPR Sensors: These sensors utilize the changes in refractive index at the sensor surface upon olanzapine binding. SPR sensors provide real-time monitoring and can be integrated into portable devices for on-site analysis [24].

FRET Sensors: Relying on energy transfer between fluorescent donor and acceptor molecules, FRET sensors offer high sensitivity and the potential for multiplexed detection of olanzapine and other analytes simultaneously [25].

7. Mass Spectrometry-Based Techniques

Liquid Chromatography-Mass Spectrometry (LC-MS)

LC-MS techniques have become increasingly prominent in olanzapine bioanalysis due to their superior sensitivity and specificity. The coupling of liquid chromatography with mass spectrometry allows for the accurate identification and quantification of olanzapine and its metabolites in various biological matrices.

Single Quadrupole LC-MS: Provides adequate sensitivity for routine clinical monitoring of olanzapine. This technique is often employed for preliminary screening and quantification [26].

Triple Quadrupole LC-MS/MS: Offers enhanced sensitivity and selectivity through multiple reaction monitoring (MRM), making it ideal for pharmacokinetic and pharmacodynamic studies. This method is highly effective for simultaneous analysis of olanzapine and its metabolites [27].

High-Resolution Mass Spectrometry (HRMS): Utilizes time-of-flight (TOF) or Orbitrap analyzers to provide high mass accuracy and resolution. HRMS is beneficial for comprehensive metabolite profiling and structural elucidation of olanzapine-related compounds [28].

8. Sample Preparation Techniques

Solid-Phase Extraction (SPE)

SPE is a widely used sample preparation technique that offers high recovery rates and minimal matrix interference. It involves the use of sorbent materials to selectively extract olanzapine from biological matrices, enhancing the overall sensitivity and specificity of the analytical method.

Liquid-Liquid Extraction (LLE)

LLE is another common sample preparation method that relies on the partitioning of olanzapine between two immiscible liquid phases. This technique is relatively simple and cost-effective but may suffer from lower extraction efficiency compared to SPE.

Microextraction Techniques

Microextraction techniques, such as solid-phase microextraction (SPME) and dispersive liquid-liquid microextraction (DLLME), offer advantages in terms of reduced solvent consumption and simplified sample preparation. These techniques are increasingly used for olanzapine analysis due to their environmental and economic benefits.

SPME: Involves the use of a coated fiber to extract olanzapine from the sample matrix. SPME is particularly useful for headspace analysis of olanzapine in complex matrices [29].

DLLME: Utilizes a dispersive solvent and an extraction solvent to rapidly extract olanzapine from the sample matrix. DLLME offers high enrichment factors and short extraction times [30].

9. Comparison and Future Prospects

Advantages and Limitations

Each bioanalytical technique has its unique advantages and limitations. Chromatographic methods, particularly HPLC-MS/MS, offer high sensitivity and specificity but require sophisticated instrumentation and extensive sample preparation. Spectroscopic methods are simpler and faster but often lack the sensitivity and selectivity needed for trace analysis. Sensor-based approaches provide rapid, on-site detection capabilities but may suffer from stability and reproducibility issues.

Emerging Trends

Future research is likely to focus on the development of hybrid techniques that combine the strengths of different analytical methods. For example, integrating chromatographic separation with sensor-based detection could provide enhanced sensitivity and selectivity while maintaining rapid analysis times. Additionally, advancements in nanotechnology and materials science are expected to drive the development of novel sensor platforms with improved performance characteristics.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(4), 1340-1344 | ISSN:2251-6727

Conclusion

The detection and analysis of olanzapine have seen significant advancements with the development of modern bioanalytical strategies. Chromatographic techniques, particularly HPLC-MS/MS and UHPLC-MS/MS, remain the cornerstone of olanzapine bioanalysis, offering high sensitivity and specificity. Spectroscopic methods provide rapid and cost-effective alternatives, while sensor-based approaches promise on-site, real-time detection capabilities. Continued innovation and integration of these techniques will further enhance analytical performance, ensuring accurate monitoring of olanzapine in clinical and pharmacokinetic applications.

Refrences

1. Bogusz MJ, Krüger KD, Maier RD. Determination of olanzapine in plasma and urine by liquid chromatography–atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999;732(2):257-269.
2. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(1):1-93.
3. Mandrioli R, Mercolini L, Raggi MA. Determination of olanzapine and desmethylolanzapine in human plasma by liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796(1):95-103.
4. Titier K, Castaing N, Scotto-Gomez E, et al. High-performance liquid chromatographic method with diode-array UV detection for the determination of thirteen psychotropic drugs in plasma after overdose. Ther Drug Monit. 2003;25(3):313-319.
5. Kubo M, Mizobuchi M, Yokoyama Y, et al. Simultaneous determination of olanzapine and its metabolites in human plasma using ultra-high-performance liquid chromatography–tandem mass spectrometry. J Pharm Biomed Anal. 2011;56(2):350-358.
6. Kumar AK, Sharma A, Shukla P, et al. Direct fluorescence spectroscopy for the determination of olanzapine in human plasma. Luminescence. 2013;28(2):233-238.
7. El-Gindy A, Emara S, Mostafa A. Spectrofluorimetric determination of olanzapine in pharmaceutical formulations and plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2003;60(8-9):1687-1695.
8. Sadeghi S, Jahani S, Shahrjerdi A. Sensitive determination of olanzapine in human serum using a modified glassy carbon electrode with multi-walled carbon nanotubes. Electrochim Acta. 2011;56(23):8713-8719.
9. Gupta VK, Singh AK, Jain R, et al. Voltammetric and amperometric determination of olanzapine in pharmaceuticals and human biological fluids. J Appl Electrochem. 2009;39(2):261-269.
10. Skládal P, Bartovská L, Chadtová Song X, et al. SPR biosensor for detection of olanzapine in human serum. Talanta. 2014;129:537-542.
11. Andreescu S, Njagi J, Ispas C, et al. Applications of advanced nanomaterials for environmental monitoring. In: Handbook of Nanomaterials for Industrial Applications. Elsevier; 2018:924-942.
12. Tóth K, Csábi K, Bella Z, et al. LC-MS determination of olanzapine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;819(2):351-354.
13. Juenke JM, Brown PI, Urry FM, et al. Therapeutic drug monitoring of atypical antipsychotics. Ther Drug Monit. 2006;28(3):369-372.
14. Follweiler JB, Barnes AJ, Scheidweiler KB, et al. High-resolution mass spectrometry for identifying metabolites of olanzapine. J Mass Spectrom. 2014;49(4):359-367.
15. Kozak M, Balbino MA, Reyes FGR. Determination of olanzapine in human plasma by solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835(1-2):91-97.
16. Bogusz MJ, Krüger KD, Maier RD. Determination of olanzapine in plasma and urine by liquid chromatography–atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999;732(2):257-269.
17. Mandrioli R, Mercolini L, Raggi MA. Determination of olanzapine and desmethylolanzapine in human plasma by liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796(1):95-103.
18. Titier K, Castaing N, Scotto-Gomez E, et al. High-performance liquid chromatographic method with diode-array UV detection for the determination of

JCHR (2024) 14(4), 1340-1344 | ISSN:2251-6727

thirteen psychotropic drugs in plasma after overdose. Ther Drug Monit. 2003;25(3):313-319.

19. Kubo M, Mizobuchi M, Yokoyama Y, et al. Simultaneous determination of olanzapine and its metabolites in human plasma using ultra-high-performance liquid chromatography–tandem mass spectrometry. J Pharm Biomed Anal. 2011;56(2):350-358.
20. Kumar AK, Sharma A, Shukla P, et al. Direct fluorescence spectroscopy for the determination of olanzapine in human plasma. Luminescence. 2013;28(2):233-238.
21. El-Gindy A, Emara S, Mostafa A. Spectrofluorimetric determination of olanzapine in pharmaceutical formulations and plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2003;60(8-9):1687-1695.
22. Sadeghi S, Jahani S, Shahrjerdi A. Sensitive determination of olanzapine in human serum using a modified glassy carbon electrode with multi-walled carbon nanotubes. Electrochim Acta. 2011;56(23):8713-8719.
23. Gupta VK, Singh AK, Jain R, et al. Voltammetric and amperometric determination of olanzapine in pharmaceuticals and human biological fluids. J Appl Electrochem. 2009;39(2):261-269.
24. Skládal P, Bartovská L, Chadtová Song X, et al. SPR biosensor for detection of olanzapine in human serum. Talanta. 2014;129:537-542.
25. Andreescu S, Njagi J, Ispas C, et al. Applications of advanced nanomaterials for environmental monitoring. In: Handbook of Nanomaterials for Industrial Applications. Elsevier; 2018:924-942.
26. Tóth K, Csábi K, Bella Z, et al. LC-MS determination of olanzapine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;819(2):351-354.
27. Juenke JM, Brown PI, Urry FM, et al. Therapeutic drug monitoring of atypical antipsychotics. Ther Drug Monit. 2006;28(3):369-372.
28. Follweiler JB, Barnes AJ, Scheidweiler KB, et al. High-resolution mass spectrometry for identifying metabolites of olanzapine. J Mass Spectrom. 2014;49(4):359-367.
29. Kozak M, Balbino MA, Reyes FGR. Determination of olanzapine in human plasma by solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835(1-2):91-97.
30. Rezaee M, Yamini Y, Faraji M. Evolution of dispersive liquid-liquid microextraction method. J Chromatogr A. 2010;1217(16):2342-2357.